Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could adding cabergoline boost ovulation in PCOS?

NCT ID NCT07168837

Disease control Sponsor: Al-Azhar University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested whether adding cabergoline to the standard drug letrozole helps women with PCOS ovulate more often. One hundred women took either letrozole alone or letrozole plus cabergoline. Researchers tracked ovulation using ultrasound starting on day 10 of the menstrual cycle.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Letrozole and cabergoline tablets
What this could lead to
If the combination works better, it could offer a more effective option for inducing ovulation in women with PCOS who struggle to conceive.
What could go wrong
This is a small, completed trial with 100 participants, so results may not apply to all women with PCOS. Adding cabergoline may also increase side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

100 people

The number who actually took part.

Started

Jan 2023

Finished

May 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 40 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women diagnosed with PCOS according to Rotterdam criteria (Rotterdam, 2004) as: 1. Menstrual anomalies like amenorrhea (no cycles in the past 6 months), oligomenorrhoea (cycles lasting longer than 35 days), or long cycles. 2. Clinical and/or biochemical hyperandrogenism. 3. Ultrasound (USG) appearance of polycystic ovaries (multiple cysts \>12 in number of 2-9 mm size). Exclusion Criteria: * Patient with liver and kidney disease. * Congenital adrenal hyperplasia. * Hypothalamic or pituitary cause of amenorrhea. * Primary hyperprolactinemia.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PCOS (polycystic ovary syndrome) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

polycystic ovary syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PCOS (polycystic ovary syndrome)

Contacts and locations

Locations

  • Al-Azhar University Hospitals

    Asyut, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.